

Title (en)
ADENOVIRUS FORMULATIONS FOR GENE THERAPY

Title (de)
ADENOVIRALE FORMULIERUNGEN ZUR GENTHERAPIE

Title (fr)
FORMULATIONS D'ADENOVIRUS POUR THERAPIE GENIQUE

Publication
EP 1109896 A4 20051102 (EN)

Application
EP 99941147 A 19990813

Priority
• US 9918515 W 19990813
• US 9660098 P 19980814

Abstract (en)
[origin: WO0009675A1] The present invention relates to a formulation allowing the preservation of viral particles and viral vectors, which is directly injectable into an organism. It relates more particularly to a formulation for the preservation of a recombinant adenovirus vector that optimally enhances the vector titer, or stabilizes the vector at refrigerator or room temperature, or both. The invention relates to compositions comprising a recombinant adenovirus vector and a concentration of human serum albumin (HSA) effective to stabilize the adenovirus vector at a temperature above the freezing point of water or to enhance a titer of the adenovirus vector compared to a titer in the absence of HSA, or both, in an aqueous buffer.

IPC 1-7
C12N 15/00; **C12N 15/63**; **A61K 48/00**; **A61K 35/00**; **C07H 21/04**

IPC 8 full level
C12N 15/09 (2006.01); **A61K 35/76** (2006.01); **A61K 38/00** (2006.01); **A61K 47/10** (2006.01); **A61K 47/26** (2006.01); **A61K 48/00** (2006.01); **A61P 9/00** (2006.01); **A61P 25/00** (2006.01); **A61P 35/00** (2006.01); **C12N 15/86** (2006.01); **C12N 15/861** (2006.01)

CPC (source: EP)
A61P 9/00 (2017.12); **A61P 25/00** (2017.12); **A61P 35/00** (2017.12); **C12N 15/86** (2013.01); **A61K 48/00** (2013.01); **C12N 2710/10343** (2013.01); **C12N 2710/10351** (2013.01)

Citation (search report)
• [X] WO 9632116 A1 19961017 - INHALE THERAPEUTIC SYST [US]
• [X] EP 0764446 A2 19970326 - BAYER AG [US]
• [X] US 4824668 A 19890425 - MELCHIOR JR FRED W [US], et al
• [A] KANEGAE Y ET AL: "A SIMPLE AND EFFICIENT METHOD FOR PURIFICATION OF INFECTIOUS RECOMBINANT ADENOVIRUS", JAPANESE JOURNAL OF MEDICAL SCIENCE AND BIOLOGY, TOKYO, JP, vol. 47, no. 3, June 1994 (1994-06-01), pages 157 - 166, XP000876518, ISSN: 0021-5112
• [A] CROYLE M A ET AL: "FACTORS THAT INFLUENCE STABILITY OF RECOMBINANT ADENOVIRAL PREPARATION FOR HUMAN GENE THERAPY", PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, NEW YORK, NY, US, vol. 3, no. 3, August 1998 (1998-08-01), pages 373 - 383, XP000881617, ISSN: 1083-7450
• [A] KOJIMA ET AL: "ADENOVIRUS MEDIATED TRANSDUCTION OF NEUROTROPHIC FACTOR GENE(S) AS A NEUROPROTECTIVE THERAPY FOR NEURODEGENERATIVE DISEASES", IKAGAKU OYO KENKYU ZAIKAN KENKYU HOKOKU, vol. 15, 1996, pages 230 - 234, XP008052124
• See references of WO 0009675A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0009675 A1 20000224; **WO 0009675 A9 20000803**; AU 5485899 A 20000306; AU 748523 B2 20020606; CA 2340682 A1 20000224; EP 1109896 A1 20010627; EP 1109896 A4 20051102; JP 2003528029 A 20030924; MX PA01001727 A 20011127

DOCDB simple family (application)
US 9918515 W 19990813; AU 5485899 A 19990813; CA 2340682 A 19990813; EP 99941147 A 19990813; JP 2000565112 A 19990813; MX PA01001727 A 19990813